<DOC>
	<DOCNO>NCT01689207</DOCNO>
	<brief_summary>This randomise , double-blind , 3-part study design investigate safety tolerability ATM-AVI . The study aim characterise pharmacokinetics ATM-AVI , drug administer alone ( ATM AVI ) combination ( ATM-AVI ) , follow single administration , follow multiple administration ATM-AVI healthy male female ( female nonchildbearing potential ) volunteer young elderly .</brief_summary>
	<brief_title>To Investigate Safety Tolerability Aztreonam-Avibactam ( ATM-AVI )</brief_title>
	<detailed_description>A Phase I , Randomised , Double-blind , 3-Part Study Healthy Young Elderly Subjects Assess Safety Tolerability , Investigate Pharmacokinetics Aztreonam Avibactam give Alone Combination ( ATM-AVI )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure Healthy young male female volunteer age 18 45 year ( inclusive ) healthy elderly volunteer age 65 older ( Part C ) suitable vein cannulation repeat venipuncture Have body mass index ( BMI ) 19 30 kg/m2 Be able understand willing comply study procedure , restriction , requirement , judge PI History clinically significant disease disorder , opinion PI , may either put volunteer risk participation study , influence result volunteer 's ability participate study History presence gastrointestinal , hepatic , renal disease , condition know interfere absorption , distribution , metabolism , excretion drug Known history severe allergy betalactam and/or Larginine History severe allergy/hypersensitivity ongoing clinically important allergy/hypersensitivity , judge PI history hypersensitivity drug similar chemical structure class ATM AVI Any clinically significant illness , medical/surgical procedure , trauma within 4 week prior first administration IP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase I , Safety , tolerability , healthy .</keyword>
</DOC>